Yu, Hong-Xia; Zhao, Mao-Mao; Pu, Zeng-Hui; Ju, Yuan-Rong; Liu, Yan
A study of community-acquired *Mycoplasma pneumoniae* in Yantai, China
Colombia Médica, vol. 49, no. 2, 2018, April-June, pp. 160-163
Facultad de Salud, Universidad del Valle, Cali, Colombia

DOI: https://doi.org/10.25100/cm.v49i2.3813

Available in: https://www.redalyc.org/articulo.oa?id=28356119005
Original Article

A study of community-acquired *Mycoplasma pneumoniae* in Yantai, China

Estudio de *Mycoplasma pneumoniae* adquirido en la comunidad en Yantai, China

Hong-Xia Yu1,2, Mao-Mao Zhao2, Zeng-Hui Pu2, Yuan-Rong Ju1 and Yan Liu2

1 Pneumology Department, Shandong Provincial Hospital. Shandong University, Jinan, China
2 Department of Infectious Diseases, Yantai Yuhuangding Hospital. Qingdao University, Yantai, China

Yu H-X, Zhao M-M, Pu Z-H, Ju Y-R, Liu Y. A study of community-acquired *Mycoplasma pneumoniae* in Yantai, China. Colomb Med (Cali). 2018; 49(2): 160-163. DOI: 10.25100/cm.v49i2.3813

© 2018. Universidad del Valle. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Abstract**

**Introduction:** Community-acquired pneumonia (CAP) is a global disease responsible for a large number of deaths, with significant economic impact. As diagnostic tools have increased in sensitivity, understanding of the etiology of CAP has begun to change. *Mycoplasma pneumoniae* is one of the major pathogens causing CAP. Macrolides and related antibiotics are first-line treatments for *M. pneumoniae*. Macrolide resistance has been spreading for 15 years and now occurs in worldwide. We undertook the first study on macrolide resistance of *M. pneumoniae* in Yantai. This may be helpful to determine the appropriate therapy for CAP in this population.

**Objective:** To investigate the rate and mechanism of macrolide resistance in Yantai.

**Methods:** Pharyngeal swab samples were collected from adult CAP patients. Samples were assayed by polymerase chain reaction (PCR) and cultivated to test for *M. pneumoniae*. Nested PCR was used to specifically amplify *M. pneumoniae* 23S rRNA gene fragments containing mutations, and amplicons were analyzed by CE-SSCP for macrolide resistance mutations. Results were confirmed by sequencing. Twenty-seven strains of *M. pneumoniae* were isolated and the activities of nine antibiotics against *M. pneumoniae* were tested in vitro.

**Results:** Out of 128 samples tested, 27 were positive for *M. pneumoniae*. Macrolide 100% macrolides resistance to *Mycoplasma pneumoniae*. The mechanism of macrolides resistance was A2063G point mutation in the sequence directly binding to macrolides in the 23S rRNA V domain in vitro. The mean pyretolytic time for the fluoroquinolone group was 4.7 ±2.9 d, which was significantly shorter than 8.2 ±4.1 d for the azithromycin group.

**Conclusions:** Macrolides are not the first-line treatment for *M. pneumoniae* respiratory tract infections in Yantai.

**Resumen**

**Introducción:** Neumonía adquirida por en la comunidad (NAC) es una enfermedad responsable por un gran número de muertes y un impacto económico importante. Debido a que el diagnóstico incrementó la sensibilidad, se cambió la etiología de la NAC. Adicionalmente, *Mycoplasma pneumoniae* es uno de los patógenos que causan la NAC. Los macrólidos y antibióticos relacionados son la primera línea de tratamiento para *M. pneumoniae*. La resistencia a macrólidos se aumentó en los últimos 15 años y ahora se encuentra distribuido en todo el mundo. Nosotros realizamos el primer estudio de resistencia a *M. pneumoniae* a los macrólidos en Yantai. Esto podría ser útil para determinar una terapia apropiada para NAC en esta población.

**Objetivo:** Investigar la tasa y el mecanismo para la resistencia a los macrólidos en Yantai.

**Métodos:** Se colectaron muestras faringeas usando un hisopo. Las muestras se analizaron mediante la reacción en cadena de la polimerasa (PCR) y por cultivo para *M. pneumoniae*. Se usó una PCR anidada para amplificar fragmentos del gen 23S rRNA específico con las mutaciones para *M. pneumoniae*. Se analizaron amplícomes por CE-SSCP para determinar la resistencia a los macrólidos. Estos resultados se confirmaron por secuenciación. Se aislaron 27 cepas de *M. pneumoniae* y se probaron nueve antibióticos in vitro.

**Resultados:** De 128 muestras, 27 fueron positivas para *M. pneumoniae*. Se determinó una resistencia a macrólidos por *Mycoplasma* del 100%. Los mecanismos de esta resistencia fue una mutación puntual A2063G en la secuencia que se une directamente a los macrólidos en el dominio 23S rRNA V in vitro. El tiempo pirotolítico medio para el grupo de fluoroquinolonas fue 4.7 ±2.9 d, que fue significativamente más corto que para el grupo de azitromicina: 8.2 ±4.1 d.

**Conclusiones:** Los macrólidos no son la primera línea de tratamiento para las infecciones del tracto respiratorio contra *M. pneumoniae* respiratorios troncos infecciones en Yantai.
Introduction

In recent years, researchers worldwide have identified *Mycoplasma pneumoniae* as one of the most common pathogens causing adult community-acquired pneumonia (CAP). In North America, Europe, Latin America, and Asia, *M. pneumoniae* pneumonia (MPP) accounts for 22%, 28%, 21%, and 20% of all pneumonia cases, respectively. In China, *M. pneumoniae* is responsible for 6.8%–38.9% of CAP etiology. Although MPP symptoms are mild in most adult patients, recent research shows that the incidence of severe MPP is increasing. Resistance of MPP to macrolide treatment is becoming a serious issue worldwide. Therefore, it is necessary to investigate drug resistance and drug resistance mechanisms of MPP, to determine the best treatment for CAP in the local community.

Materials and Methods

Inclusion criteria

Our study recruited CAP patients from the outpatient clinic and hospital admissions at Yantai Yuhuangding Hospital and its Laishan branch between January 2015 and January 2016. The inclusion criteria for this study were: 1) age >18 years; 2) meeting the diagnostic criteria for CAP issued by the American Thoracic Society and Infectious Diseases Society of America in 2007; and 3) diagnosis of *M. pneumoniae* infection by positive pharyngeal swab polymerase chain reaction (PCR) test, according to the British Thoracic Society CAP guidelines. Patients were excluded if they: 1) presented with lung disease, such as lung abscess, aspiration pneumonia, or obstructive pneumonia; 2) were immunosuppressed, including AIDS patients, organ transplantation patients, patients taking two or more types of immunosuppressive drugs such as azathioprine, cyclosporine, and cyclophosphamide, or patients with malignant tumors who were actively receiving chemotherapy, radiotherapy, or surgical treatment; 3) were readmitted within 14 days from hospital discharge; 4) were pregnant or within 6 weeks after childbirth; 5) were previously enrolled in a similar study, were unable to provide medical history, or were unwilling to participate in this study.

Patients

One hundred and thirty CAP patients were enrolled in this study. Two patients were lost to follow-up. Among the 128 cases finally enrolled, 27 were positive for *M. pneumoniae* (21.1%), including 11 males and 16 females aged between 18 and 72 years (average age 36 ± 5.7).

*Mycoplasma pneumoniae* isolation and identification

Patients’ clinical information was recorded. Pharyngeal swabs were obtained from each patient for *M. pneumoniae* identification and isolation. Pharyngeal swabs were either inoculated within 24 h after collection into 1 mL of CM403 medium (Oxoid, UK) with *Mycoplasma* Supplement G (Oxoid, UK) and incubated at 37° C, or preserved at -20° C. After 6 weeks, if the liquid medium changed from red to yellow, suggesting utilization of glucose, 0.2 mL of the culture was spread onto agar medium and incubated at 37° C with 5% CO₂ for 7-14 days. A single colony was then isolated and subcultivated three times until “fried-egg” colonies, typical of *M. pneumoniae*, were observed. Identification of *M. pneumoniae* strains was performed using a molecular method. Genomic DNA was extracted from 2.0 mL of culture with single "fried-egg" colonies using the QIAamp DNA Mini Kit (QIAGEN, Germany), according to the manufacturer's instructions. The *M. pneumoniae*-specific 16s rRNA gene fragment was amplified from the extracted DNA by PCR with the primer sequences used by Morozumi et al. The appearance of the target band on an electrophoresis gel indicated a positive *M. pneumoniae* infection.

Antimicrobial susceptibility of *M. pneumoniae*

In vitro antimicrobial susceptibility tests were performed using erythromycin, azithromycin, moxifloxacin, levofloxacin, and tetracycline. The procedures and interpretation of results were conducted according to the "Methods for Antimicrobial Susceptibility Testing for Human Mycoplasma; Approved Guideline". *M. pneumoniae* reference strain FH (ATCC15531) was used as drug-sensitive control. Standard drugs were purchased from China Pharmaceutical Biological Products Analysis Institute.

Detection of macrolide resistance-related genes

Domain V of the *M. pneumoniae* 23s rRNA gene was amplified by nested PCR (nPCR) of extracted DNA from clinical isolates, using previously described protocols and primer sequences. The nPCR products, including the reference strain, were sequenced (Sangon Biotech Co, Ltd., Shanghai, China). DNA sequences were compared to the *M. pneumoniae* strain FH sequence (GenBank accession no. CP002077.1) using BLAST.

Statistical analysis

Data were analyzed by a t-test using SPSS 19.0 software. *p* < 0.05 suggested a statistically significant difference.

This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Qingdao University. Written informed consent was obtained from all participants.

Results

Antimicrobial susceptibility

Eight of the 27 patients testing positive for *M. pneumoniae* used antimicrobial drugs 72 h prior to enrollment into the study. This included two patients using cephalosporin (7.4%), two patients using clindamycin (7.4%), three patients using macrolides (11.1%), and one patient using quinolones. All 27 strains (100%) of *M. pneumoniae* isolated from patients in this study were found to be resistant to macrolides. No quinolone- or tetracycline-resistant strains were identified (Table 1).

The MICs of erythromycin and clarithromycin (64-256 mg/L) were higher than that of azithromycin (16-128 mg/L). All 27 clinical isolates were susceptible to tetracyclines (tetracycline and minocycline) and fluorquinolones (levofloxacin, ciprofloxacin, moxifloxacin, and gatifloxacin).

23S rRNA mutation in macrolide-resistant strains

We identified an A2063G point mutation in the sequence directly binding to macrolides in the 23S rRNA V domain of all 27 macrolide-resistant *M. pneumoniae* strains.

Comparison between the clinical efficacy of azithromycin and fluoroquinolones

Among the 27 macrolide-resistant clinical strains, 9 cases were treated with azithromycin and 18 cases were treated with...
Table 1. *In vitro* drug sensitivity of the 27 isolated *M. pneumoniae* strains.

| Strain No. | Erythromycin | Clarithromycin | Azithromycin | Tetracycline | Minocycline | Moxifloxacin | Gatifloxacin | Levofloxacin | Ciprofloxacin |
|------------|--------------|---------------|-------------|--------------|------------|--------------|-------------|-------------|-------------|
| 1          | 128          | 128           | 64          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 1.0         |
| 2          | 64           | 64            | 16          | 0.25         | 0.125      | 0.032        | 0.064       | 0.25         | 0.5         |
| 3          | 128          | 128           | 64          | 0.50         | 0.500      | 0.125        | 0.125       | 0.50         | 1.0         |
| 4          | ≥256         | ≥256          | ≥256        | 0.25         | 0.125      | 0.064        | 0.064       | 0.50         | 0.5         |
| 5          | 64           | 128           | 32          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 0.5         |
| 6          | 64           | 64            | 32          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 0.5         |
| 7          | 128          | 128           | 32          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 0.5         |
| 8          | 128          | 128           | 64          | 0.50         | 0.500      | 0.064        | 0.064       | 0.50         | 1.0         |
| 9          | 128          | 128           | 64          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 0.5         |
| 10         | 64           | 64            | 32          | 0.25         | 0.250      | 0.032        | 0.064       | 0.25         | 0.5         |
| 11         | ≥256         | ≥256          | 128         | 0.25         | 0.125      | 0.064        | 0.064       | 0.50         | 0.5         |
| 12         | 128          | 128           | 32          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 0.5         |
| 13         | ≥256         | ≥256          | 128         | 0.25         | 0.125      | 0.064        | 0.064       | 0.50         | 0.5         |
| 14         | 128          | 128           | 64          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 0.5         |
| 15         | ≥256         | ≥256          | 64          | 0.25         | 0.125      | 0.064        | 0.064       | 0.50         | 0.5         |
| 16         | 128          | 128           | 64          | 0.25         | 0.125      | 0.064        | 0.064       | 0.50         | 0.5         |
| 17         | ≥256         | ≥256          | 128         | 0.25         | 0.125      | 0.064        | 0.064       | 0.50         | 0.5         |
| 18         | ≥256         | ≥256          | 64          | 0.25         | 0.125      | 0.064        | 0.064       | 0.50         | 0.5         |
| 19         | 128          | 128           | 64          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 0.5         |
| 20         | ≥256         | ≥256          | 128         | 0.25         | 0.125      | 0.064        | 0.064       | 0.50         | 0.5         |
| 21         | ≥256         | ≥256          | 64          | 0.25         | 0.125      | 0.064        | 0.064       | 0.50         | 0.5         |
| 22         | 128          | 128           | 64          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 1.0         |
| 23         | 128          | 128           | 64          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 1.0         |
| 24         | 128          | 128           | 64          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 1.0         |
| 25         | 256          | 256           | 16          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 1.0         |
| 26         | 128          | 128           | 64          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 1.0         |
| 27         | 128          | 128           | 64          | 0.50         | 0.250      | 0.064        | 0.064       | 0.50         | 1.0         |
| Control    | ≤Control 64e | ≤Control 64e  | ≤Control 64e| 0.25         | 0.125      | 0.032        | 0.064       | 0.25         | 0.5         |

fluoroquinolones (10 cases with levofloxacin and 8 cases with moxifloxacin). The mean pyretolytic time for the fluoroquinolone group was 4.7 ± 2.9 d, which is significantly shorter than 8.2 ± 4.1 d for the azithromycin group (p < 0.05). There was no statistical difference in the time for cough relief between the azithromycin group (13.5 ± 7.4 d) and the fluoroquinolone group (8.6 ± 5.1 d) (Table 2).

**Discussion**

*M. pneumoniae* is the main cause of CAP in humans and is usually transmitted by close contact with infected patients. Studies have found that *M. pneumoniae* has replaced *Streptococcus pneumoniae* as the major CAP pathogen, accounting for 10%–30% of cases. Due to the lack of a cell wall in *M. pneumoniae* and fewer contraindications, macrolides have been the first choice for the clinical treatment of MPP.

Recently, more than 60% of macrolide-resistant *M. pneumoniae* strains in pediatric patients were shown to have high resistance to 14- and 15-membered ring macrolides. In contrast to pediatric patients, the prevalence of macrolide-resistant *M. pneumoniae* infection in adult patients in the United States and the UK is low at 0–23% and 9.3%, respectively. However, several Chinese studies have reported a significantly higher percentage of macrolide-resistant *M. pneumoniae* strains, up to 90%.

In this study, we found that the prevalence of macrolide-resistant *M. pneumoniae* was 100% in Yantai, which is significantly higher than previous studies. This may be due to a lack of previous research into antimicrobial resistance status and the abuse of macrolides in local regions. As macrolides do not require a skin test and have few side effects, they have become commonly used antibiotics at home. Our study found that 37.5% (3/8) of patients had used macrolides before seeing a doctor. We also found that macrolide prescriptions were common in outpatient services of the Pediatric Department and the Respiratory Department in our hospital.

The mechanism of macrolide-resistance has been widely explored. Macrolide resistance in *M. pneumoniae* was found to be highly related to mutations in domain V of the 23S rRNA gene. The A2063G and A2064G mutations were identified as the most prevalent mutations related to macrolide resistance. The A2063G mutation, which often leads to high levels of macrolide resistance, can occur in Chinese populations at a frequency of more than 95%. In our study, 27 macrolide-resistant *M. pneumoniae* strains harbored the A2063G mutation in the 23S rRNA gene. This may be one of the reasons for 100% macrolide resistance in Yantai, China.

This study has several disadvantages. Firstly, the sample size was small. Secondly, due to concerns about macrolide resistance, MPP patients were mostly treated with fluoroquinolone and therefore, we were unable to analyze the effect of macrolide-resistance on prognosis. Thirdly, in this study we defined the diagnosis of MPP as isolation of *M. pneumoniae* in the pharyngeal swab. However, less than a quarter of patients had their diagnosis confirmed by paired serum antibody tests.

In summary, this study found that macrolide-resistant *M. pneumoniae* in adult CAP in Yantai is a major problem, with a resistance rate of 100%. Rigorous supervision of the administration of macrolides is urgently needed. Further studies on the genome of *M. pneumoniae* could provide us with information regarding drug resistance trends. At present, fluoroquinolone and tetracycline have good antimicrobial activity against *M. pneumoniae* in vitro. However, in Yantai, the abusive use of fluoroquinolones in fish and poultry industries could lead to the development of resistant *M. pneumoniae* strains. Management of antimicrobial treatment resistance...
Table 2. The effect comparison of the fluoroquinolones and macrolides groups.

| Groups                      | Macrolides (N= 9) | Fluoroquinolones (N= 18) | p value |
|-----------------------------|-------------------|--------------------------|---------|
| Total duration of fever (x̄ ±σ) | 8.22 ±4.15        | 4.72 ±2.89               | <0.05 (0.017) |
| Total duration of cough (x̄ ±σ) | 13.56 ±7.37       | 8.67 ±5.05               | >0.05 (0.053) |

1. Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007; 175:1086-93.

2. von Baum H, Welte T, Marre R, Suttorp N, Lück C, Ewig S. Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). BMC Infect Dis. 2009; 9:62.

3. Tao LL, Hu BJ, He LX, Wei L, Xie HM, Wang BQ, et al. Etiology and antimicrobial resistance of community-acquired pneumonia in adult patients in China. Chin Med J (Engl). 2012; 125:2967-72.

4. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis. 2010; 51:189-94.

5. Izumikawa K, Izumikawa K, Takazono T, Kosai K, Morinaga Y, Nakamura S, et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae: a review of the japanese literature. J Infect Chemother. 2014; 20:181-5.

6. Apfalter P, Stoisser B, Barousch W, Nehr M, Kramer L, Burgmann H. Community-acquired bacteria frequently detected by means of quantitative polymerase chain reaction in nosocomial early-onset ventilator-associated pneumonia. Crit Care Med. 2005; 33:1492-8.

7. Muir MT, Cohn SM, Louden C, Kannan TR, Baseman JB. Novel toxin assays implicate Mycoplasma pneumoniae in prolonged ventilator course and hypoxemia. Chest. 2011; 139:305-10.

8. Miyashita N, Kawai Y, Inamura N, Tanaka T, Akaike H, Teranishi H, et al. Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother. 2015; 21:153-60.

9. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. Macrolide resistance in Mycoplasma pneumoniae, Israel. 2010. Emerg Infect Dis. 2011; 17:1079-82.

10. Zhou Z, Li X, Chen X, Luo F, Pan C, Zheng X, et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China. Antimicrob Agents Chemother. 2015; 59:1048-51.

11. Zheng X, Lee S, Selvarangan R, Qin X, Tang YW, Stiles J, et al. Macrolide-resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis. 2015; 21:1470-2.

12. Ishiguro N, Koseki N, Kaiho M, Kikuta H, Togashi T, Obi K, et al. Regional differences in prevalence of macrolide resistance among pediatric Mycoplasma pneumoniae infections in Hokkaido, Japan. Jpn J Infect Dis. 2016; 69:186-90.

13. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72.

14. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009; 64 Suppl 3:i1-55.

15. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23SrRNA gene mutation. Antimicrob Agents Chemother. 2005; 49:2302-6.

16. Clinical and Laboratory Standards Institute (CLS). Methods for antimicrobial susceptibility testing for human Mycoplasma; approved guideline. CLSI document M43-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.

17. Daxboeck F, Krause R, Wenisch C. Laboratory diagnosis of Mycoplasma pneumoniae infection. Clin Microbiol Infect. 2003; 9:263-73.

18. Principi N, Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J Antimicrob Chemother. 2013; 68:506-11.

19. Qu J, Gu L, Wu J, Dong J, Pu Z, Gao Y, et al. Accuracy of IgM antibody testing, FQ-PCR and culture in laboratory diagnosis of acute infection by Mycoplasma pneumoniae in adults and adolescents with community-acquired pneumonia. BMC Infect Dis. 2013; 13:172.

20. Diaz MH, Benitez AJ, Winchell JM. Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013. J Clin Microbiol. 2015; 53:124-30.

21. Brown RJ, Macfarlane-Smith L, Phillips S, Chalker VJ. Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. Euro Surveill. 2015; 20:30078.

22. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013; 57:1521-3.

23. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008; 52:348-50.